Abstract
Background Impact of COVID-19 upon acute care admission rates and patterns are unknown. We sought to determine the change in rates and types of admissions to tertiary and specialty care hospitals in the COVID-19 era compared with pre-COVID-19 era.
Methods Acute care admissions to the largest tertiary care referral hospital, designated national referral centers for cardiac, cancer and maternity hospital in the State of Qatar during March 2020 (COVID-19 era) and January 2020 and March 2019 (pre-COVID-19 era) were compared. We calculated total admissions, and admissions for eight specific acute care conditions, in-hospital mortality rate and length of stay at each hospital.
Results A total of 18,889 hospital admissions were recorded. A sharp decline ranging from 9%-75% was observed in overall admissions. A decline in both elective and non-elective surgeries was observed. A decline of 9%-58% was observed in admissions for acute appendicitis, acute coronary syndrome, stroke, bone fractures, cancer and live births, while an increase in admissions due to respiratory tract infections was observed. Overall length of stay was shorter in the COVID-19 period possibly suggesting lesser overall disease severity, with no significant change in in-hospital mortality. Unadjusted mortality rate for Qatar showed marginal increase in the COVID-19 period.
Conclusions We observed a sharp decline in acute care hospital admissions, with a significant decline in admissions due to seven out of eight acute care conditions. This decline was associated with a shorter length of stay, but not associated with a change in in-hospital mortality rate.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This study was funded by the Medical Research Center, Hamad Medical Corporation, Doha, Qatar. (PI: Prof. Adeel A. Butt)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the Institutional Review Board at Hamad Medical Corporation (MRC-05-034).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
aabutt{at}hamad.qa
akartha{at}hamad.qa
nmasoodi{at}hamad.qa
aazad{at}hamad.qa
nasaad{at}hamad.qa
malhomsi{at}hamad.qa
hsaleh1{at}hamad.qa
rbertollini{at}moph.gov.qa
asamra{at}hamad.qa
Drafting of the manuscript: AAB, ABK, AA
Data acquisition: AAB
Data analysis: AAB, AA
Data interpretation: AAB, AK, NAM, AMA, NAA, MUAH, HAHS, RB, AA
Critical appraisal and review: AAB, ABK, NAM, AMA, NAA, MUAH, HAHS, RB, AA
Authorship Statement: Dr. Butt had complete access to data at all times and accepts the responsibility of the integrity of this article.
Declarations: Authors declare no financial conflict of interest regarding the content of this article. No data are available for public access.
Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent official government views or policy of the State of Qatar or Hamad Medical Corporation.
Funding: This study was funded by the Medical Research Center, Hamad Medical Corporation, Doha, Qatar. (PI: Prof. Adeel A. Butt)
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos